While the clinical promise of the Cancer Immunotherapy Market is vast, the critical issue of affordability remains a significant hurdle. As many of these treatments remain high-cost, the industry is exploring innovative financing models, including outcomes-based payment plans where the manufacturer is paid only if the therapy demonstrates the expected efficacy. These models are gaining traction...